Natera, Inc. Stock

Equities

NTRA

US6323071042

Healthcare Facilities & Services

Real-time Estimate Cboe BZX 09:46:46 2024-04-22 am EDT 5-day change 1st Jan Change
85.54 USD +0.30% Intraday chart for Natera, Inc. -4.45% +37.93%
Sales 2024 * 1.34B Sales 2025 * 1.59B Capitalization 10.3B
Net income 2024 * -280M Net income 2025 * -142M EV / Sales 2024 * 7.38 x
Net cash position 2024 * 414M Net cash position 2025 * 508M EV / Sales 2025 * 6.17 x
P/E ratio 2024 *
-36.8 x
P/E ratio 2025 *
-73 x
Employees 3,288
Yield 2024 *
-
Yield 2025 *
-
Free-Float 95.26%
More Fundamentals * Assessed data
Dynamic Chart
Natera Insider Sold Shares Worth $7,265,651, According to a Recent SEC Filing MT
Natera Insider Sold Shares Worth $634,797, According to a Recent SEC Filing MT
Goldman Sachs Adjusts Natera Price Target to $100 From $90, Maintains Buy Rating MT
Natera, Inc. Announces Publication of Larger Prospective dd-cfDNA Study in Kidney Transplantation CI
Natera, Inc. Announces New Data from Two Studies Extending the Clinical Validation of Its Prospera Heartd-cfDNA Test for Heart Transplant Recipients CI
North American Morning Briefing : Inflation Data, -2- DJ
Natera Reports Positive Surveillance Analysis From Phase 3 Study of Bladder Cancer Test; Shares Rise MT
Bernstein Upgrades Natera to Outperform From Market Perform, Raises Price Target to $120 From $86 MT
Natera Insider Sold Shares Worth $2,468,822, According to a Recent SEC Filing MT
Natera, Inc. and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 A Randomized, Phase Ii/Iii Adjuvant Trial in Urothelial Cancer CI
Natera, Inc. Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera?? in Stage II Colorectal Cancer CI
Natera Insider Sold Shares Worth $534,331, According to a Recent SEC Filing MT
Natera Insider Sold Shares Worth $824,092, According to a Recent SEC Filing MT
Natera Insider Sold Shares Worth $16,694,485, According to a Recent SEC Filing MT
Natera Receives Commercial Insurance Coverage of Genetic Test for Transplant Risks MT
More news
1 day+0.30%
1 week-4.45%
Current month-5.53%
1 month-6.41%
3 months+29.57%
6 months+115.57%
Current year+37.93%
More quotes
1 week
83.13
Extreme 83.13
91.50
1 month
83.13
Extreme 83.13
98.82
Current year
58.53
Extreme 58.53
98.82
1 year
36.90
Extreme 36.9
98.82
3 years
26.10
Extreme 26.1
129.09
5 years
16.87
Extreme 16.87
129.09
10 years
6.52
Extreme 6.52
129.09
More quotes
Managers TitleAgeSince
Chief Executive Officer 45 10-11-30
Founder 51 03-10-31
Founder 51 03-10-31
Members of the board TitleAgeSince
Director/Board Member 58 14-10-31
Director/Board Member 50 06-12-31
Director/Board Member 76 14-01-31
More insiders
Date Price Change Volume
24-04-22 86.52 +1.45% 11 401
24-04-19 85.28 -2.29% 2,526,074
24-04-18 87.28 -3.38% 1,172,503
24-04-17 90.33 +0.01% 694,057
24-04-16 90.32 -0.11% 1,389,481

Delayed Quote Nasdaq, April 22, 2024 at 09:31 am EDT

More quotes
Natera, Inc. is a diagnostics company, which is focused on the development and commercialization of molecular testing services, applying its technology in the fields of women’s health, oncology and organ health. Its cell-free deoxyribonucleic acid (cfDNA) technology combines its molecular assays, which reliably measure many informative regions across the genome from samples as small as a single cell. The Company's product offerings include Panorama Non-Invasive Prenatal Test (NIPT), Vistara, Horizon Carrier Screening, Spectrum Preimplantation Genetics, Anora Miscarriage Test, Empower, and Prospera. The Company also offers Constellation, a cloud-based software platform that enables laboratory customers to gain access through the cloud to the Company’s algorithms and bioinformatics in order to validate and launch tests based on the Company’s technology. Its NIPT screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
85.28 USD
Average target price
102.6 USD
Spread / Average Target
+20.36%
Consensus